Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 6/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.42 |
| ▸ | ITGAV | P06756 | 8/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.36 |
| ▸ | DRD3 | P35462 | 4/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382764 | 0.88 | ITGB3 (0.51) | ITGB3ITGAVITGA2BDRD2DRD3 | |
| SCHEMBL27551456 | 0.88 | ITGB3 (0.51) | ITGB3ITGAVITGA2BDRD2DRD3 | |
| SCHEMBL6499964 | 0.87 | KAT6A (0.43) | KAT6AITGB3ITGAVITGA2BDRD2 | |
| SCHEMBL6505536 | 0.86 | ITGB3 (0.48) | KAT6AITGB3ITGAVITGA2B | |
| SCHEMBL6499908 | 0.86 | ITGB3 (0.41) | KAT6AITGB3ITGAVITGA2BDRD2 | |
| SCHEMBL6497483 | 0.86 | ITGB3 (0.60) | KAT6AITGB3ITGAVITGA2B | |
| SCHEMBL6496638 | 0.85 | ITGB3 (0.57) | KAT6AITGB3ITGAVITGA2B | |
| SCHEMBL383239 | 0.85 | ITGB3 (0.55) | ITGB3ITGAVITGA2B | |
| SCHEMBL382205 | 0.85 | ITGB3 (0.42) | ITGB3ITGAVITGA2BDRD2DRD3 | |
| SCHEMBL6499638 | 0.85 | ITGB3 (0.41) | KAT6AITGB3ITGAVITGA2BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | AJITO KEIICHI (JP) | 2005-03-17 | — | — | US | claimed |
| EP-1229024-A1 | m-SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING INTEGRIN ALPHA-V BETA-3 ANTAGONISM | MEIJI SEIKA KAISHA LTD. (JP) | 2002-08-07 | — | — | EP | claimed |
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | AJITO KEIICHI (JP) | 2005-03-17 | — | — | US | disclosed |
| EP-1229024-A1 | m-SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING INTEGRIN ALPHA-V BETA-3 ANTAGONISM | MEIJI SEIKA KAISHA LTD. (JP) | 2002-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | ITGAV, ITGB3, ITGA4 | KAT6A 1672/4885ITGB3 2/4885ITGAV 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.